MBX Biosciences (MBX) Capital Expenditures (2023 - 2026)

MBX Biosciences has disclosed Capital Expenditures across 4 years of filings, most recently posting $437000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $437000.0, down 12.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 38.9% YoY), and the FY2025 annual result was $1.9 million, up 120.71% from the prior year.
• Capital Expenditures came in at $437000.0 for Q1 2026 at MBX Biosciences, down from $793000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $858000.0 in Q4 2024 to a low of -$54000.0 in Q3 2024.
• The 4-year median for Capital Expenditures is $317000.0 (2025), against an average of $325800.0.
• Across the five-year window, Capital Expenditures jumped 4666.67% in 2024 and decreased 12.95% in 2026, its largest moves.
• MBX Biosciences' Capital Expenditures stood at $18000.0 in 2023, then surged by 4666.67% to $858000.0 in 2024, then decreased by 7.58% to $793000.0 in 2025, then sank by 44.89% to $437000.0 in 2026.
• The last three Capital Expenditures figures came in at $437000.0 (Q1 2026), $793000.0 (Q4 2025), and $399000.0 (Q3 2025), per Business Quant data.